John Deflice, myeloma patient, with backdrop of ASH conference in Orlando 2019

Shrimp Options

John DeFlice |

“Anyway, like I was sayin’, shrimp is the fruit of the sea. You can barbecue it, boil It, broil it, bake it, sauté it. Dey’s un, shrimp-kabobs, shrimp creole, shrimp gumbo, pan fried, deep fried, stir-fried. There’s pineapple shrimp, lemon shrimp, coconut shrimp, pepper shrimp, shrimp soup, shrimp stew, shrimp salad, shrimp and potatoes, shrimp […]

Cindy Chmielewski on ASH background

Immunotherapy – Front and Center

Cynthia Chmielewski |

Immunotherapy was front and center at this year’s American Society of Hematology’s (ASH) meeting. There even was an Education Session presented by Drs. Shah, Cohen and Borello on this topic. When I first attended the ASH Annual Meeting in 2012, immunotherapy was still in its infancy. The treatments that were being examined in clinical trials back […]

How Things Have Changed

Linda Huguelet |

I was diagnosed in 2010, and this is my seventh year to attend the American Society of Hematology (ASH) conference. As we are winding up the a last day of the conference, I can’t believe how much progress has been made. I know it’s never fast enough from a patient’s perspective, but nonetheless, the progress […]

Monoclonal Antibodies Take ASH by Storm

Linda Huguelet |

Monoclonal antibodies are becoming the backbone of treatments for relapsed and refractory patients, but they are also making their way into the front-line setting for newly diagnosed patients. The first official day of the American Society of Hematology (ASH) Annual Conference was filled presentations, posters, and exhibits touting the effectiveness of this drug class. I would […]

ASH Is the Most Important Conference for Myeloma Patients and Doctors

Jack Aiello |

There is no other single conference where so much information is presented about myeloma. Information about so many topics is provided:  how to treat MM patients in various stages; results of phase II & III trials which may indicate upcoming FDA approvals; pre-clinical research focusing on myeloma targets and cell understanding; and more. Soon I’ll be […]

Four years ago….

Yelak Biru |

“During a two-week span in November, the Food and Drug Administration approved three new drugs to treat multiple myeloma, a rare form of blood cancer that kills an estimated 11,000 Americans a year. The approvals, along with others in recent years, are beginning to alter the prognosis of a disease that once amounted to a death […]